QuantiWise

The United States and Canada operate under fundamentally different pharmaceutical market access models. This article compares FDA and Health Canada approval timelines, drug pricing regulation, HTA review, and provincial reimbursement pathways. The United States and Canada share the longest international land border in the world, stretching over 8,800 kilometers. Trade flows freely. Talent moves back and forth. The systems look similar from a distance. But in pharmaceuticals, the similarities largely stop at the border. Despite geographic proximity, the two countries operate under fundamentally different commercialization models. And those differences shape launch sequencing, pricing strategy, revenue realization, and long term portfolio planning. Market Gravity Matters The US accounts for roughly 35 to 45 percent of global pharmaceutical revenue. Canada represents approximately 2 percent of the global market. That imbalance alone influences global strategy. When a company is deciding w...